23andMe Investor Presentation Deck

1 Phase 1 Phase 1/2a Study of 23ME'610 in Patients with Locally Advanced or Metastatic Solid Malignancies Patients with locally advanced, unresectable or metastatic solid tumors that have progressed after or are inappropriate for standard therapy Study Design Y Openlabel Part A (n = 26) Monotherapy Dose Escalation (IV Infusion Q3W) Accelerated Titration 3+3 Cohorts RP2D / MTD x Non- Randomized Multi-center Part B (n = 75) (~15/cohort) Neuroendocrine Cancers Small Cell Lung Cancer Ovarian Cancer Renal Clear Cell Cancer MSI-H & TMB-H Cancers Adolescent Cancers Primary Objectives Part A: Safety (DLTS, AES) Part B: Efficacy (ORR) Secondary and Exploratory Efficacy (ORR [RECIST and iRECIST]), DOR, PFS, OS) and Safety > Pharmacokinetics Pharmacodynamic biomarkers Abbreviations: AEs: Adverse Events; DLT: Dose limiting toxicity; DOR: duration of response; IV: intravenous; ORR: Objective Response Rate; OS: Overall Survival; PFS: Progression Free Survival; Q3W: every three weeks; RECIST: Response Evaluation Criteria in Solid Tumors; RP2D: Recommended Phase 2 Dose Copyright © 2023 23and Me, Inc. 23andMe 45

View entire presentation